Erectile dysfunction and diabetes: A melting pot of circumstances and treatments

G Defeudis, R Mazzilli, M Tenuta… - Diabetes/metabolism …, 2022 - Wiley Online Library
Diabetes mellitus (DM), a chronic metabolic disease characterised by elevated levels of
blood glucose, is among the most common chronic diseases. The incidence and prevalence …

Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions

SH Francis, MA Blount, JD Corbin - Physiological reviews, 2011 - journals.physiology.org
The superfamily of cyclic nucleotide (cN) phosphodiesterases (PDEs) is comprised of 11
families of enzymes. PDEs break down cAMP and/or cGMP and are major determinants of …

PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer

A Das, D Durrant, FN Salloum, L **… - Pharmacology & …, 2015 - Elsevier
Abstract The phosphodiesterase 5 (PDE5) inhibitors, including sildenafil (Viagra™),
vardenafil (Levitra™), and tadalafil (Cialis™) have been developed for treatment of erectile …

Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference)

JB Kostis, G Jackson, R Rosen… - The American journal of …, 2005 - Elsevier
Recent studies have highlighted the relation between erectile dysfunction (ED) and
cardiovascular disease. In particular, the role of endothelial dysfunction and nitric oxide in …

Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism (s) of action

KE Andersson, WC De Groat, KT McVary… - Neurourology and …, 2011 - Wiley Online Library
Background The PDE5 inhibitor tadalafil is investigation for the treatment of lower urinary
tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Several clinical …

Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links

C Vlachopoulos, K Rokkas, N Ioakeimidis… - European urology, 2007 - Elsevier
OBJECTIVE: Erectile dysfunction (ED) may be the early clinical manifestation of a
generalized vascular disease and carries an independent risk for cardiovascular events …

Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease

C Vlachopoulos, K Aznaouridis… - European heart …, 2006 - academic.oup.com
Aims Erectile dysfunction (ED) confers an independent cardiovascular risk. We investigated
the role of low-grade inflammation and endothelial dysfunction in ED patients with or without …

Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis

A Tsertsvadze, HA Fink, F Yazdi… - Annals of internal …, 2009 - acpjournals.org
Background: Erectile dysfunction (ED) is a common male sexual disorder. The relative
benefits and harms of pharmacologic therapies for ED, as well as the value of hormonal …

Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized …

H Porst, F Giuliano, S Glina, D Ralph, AR Casabé… - European urology, 2006 - Elsevier
BACKGROUND: Erectile dysfunction (ED) is a chronic disease; however, therapy is currently
administered as needed with oral phosphodiesterase 5 (PDE5) inhibitors like tadalafil …

Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies

V Phé, M Rouprêt - Diabetes & metabolism, 2012 - Elsevier
AIM: This review aimed to provide an update of the epidemiology, pathophysiology and
management of erectile dysfunction (ED) in diabetes patients. METHODS: Data on the …